Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).
   Google Scholar   
Citation:
J Clin Oncol vol 32 (15_suppl) 506
Meeting Instance:
ASCO 2014
Year:
2014
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Secondary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
2304  
Program:
OGC
Primary Committee:
Breast
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                               
Networks:
 
Study
CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: